This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

The scientists used two preclinical models of absence epilepsy to test their hypothesis. Both models feature animals genetically predisposed to absence seizures that consistently and reliably develop ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Absence seizure, formerly known as petit mal seizure, is a type of short seizure that usually causes a person to briefly lose focus, stare into space, and lose awareness of their surroundings. These ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy- MIAMI, Feb.

When we hear about epilepsy, we often think of seizures, but there is much more to this neurological disorder. Epilepsy is ...

The multicenter retrospective study included 543 mostly White women of childbearing age with IGE according to International League Against Epilepsy (ILAE) diagnostic criteria — a population facing ...

“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, ...